

**Question for written answer E-001391/2025
to the Commission**
Rule 144
Tilly Metz (Verts/ALE)

Subject: Compliance with Directive 2010/63/EU for antibody production methods

In 2022, 477 632 uses of animals were recorded for routine production purposes, including for antibody production, despite the availability of a validated non-animal method recommended by the European Centre for the Validation of Alternative Methods (ECVAM). Of particular concern is the fact that 49 309 uses involved the ascites method, which ECVAM has strongly discouraged since 1998. France accounted for 97 % of these uses and has reported a 34 % increase since 2021.

Given that Directive 2010/63/EU requires the use of non-animal methods where they are available:

1. What steps is the Commission taking to ensure that the Member States comply with this requirement?
2. Will the Commission initiate infringement proceedings against countries such as France, where there is a persistent failure to transition to non-animal methods?

Submitted: 4.4.2025